Published in MedTech Strategist, May 2018
Authors: Dr. Oded Ben-Joseph and Seth Bensussen
Not long ago, tPA was the only front-line treatment for acute ischemic stroke. But a second generation of mechanical thrombectomy devices, including stent retrievers and aspiration-based reperfusion devices, has demonstrated significant efficacy against ischemic stroke, providing the impetus for renewed device innovation and new care delivery strategies.
Next-generation mechanical thrombectomy devices will be the chief driver of growth in the neurovascular device market. New clinical data suggesting that interventional treatment even up to 24 hours after stroke onset is beneficial for some patients could almost triple the number of patients eligible for treatment.
Tuesday, July 23 6:00-7:30pm Cost: This event is hosted by Dr. Oded Ben-Joseph (Darwin 1988), Managing Director, Outcome Capital, LLC, and is free to attend with prior RSVP. Outcome Capital, LLC 99 High Street, Suite 2900 Boston, MA RSVP to Megan Cokely at firstname.lastname@example.org Cambridge in America’s Boston Regional Committee invites you to another exclusive event for […]Read More
Outcome Capital Secures Growth Capital for Whisker Labs November 26, 2019, Reston, VA Outcome Capital, an investment banking firm that serves middle market growth companies in the technology and life sciences space, is pleased to announce that Whisker Labs, Inc. (the “Company”) has secured growth capital from State Farm Ventures and Ferguson Ventures along with […]Read More